Singapore, June 27 -- Bayer and Tsinghua University (THU) have announced the signing of the sixth phase of the collaboration agreement, aiming to further facilitate the translation of scientific research outcomes into drug discovery and development, focused on key selected areas of interests, such as oncology, cardiovascular and renal diseases, neurology & rare diseases, and immunology, accelerating cutting-edge scientific research across the pharmaceutical value chain.

Under the agreement, Germany headquartered pharmaceutical company Bayer will continue to provide funding and support for joint research projects over the next three years, as well as to scientists at THU in recognition of their outstanding contributions in life sciences a...